Toll-like Receptor 3-mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance

Overview

Journal Cancer Res

Specialty Oncology

Date 2010 Mar 18

PMID 20233880

Citations 58

Authors

Arnold I Chin

Andrea K Miyahira

Anthony Covarrubias

Juli Teague

Beichu Guo

Paul W Dempsey

Genhong Cheng

Affiliations

Soon will be listed here.

Abstract

Inflammation has increasingly been recognized as a critical component influencing tumor growth. Recent reports have revealed conflicting evidence for the role of Toll-like receptors (TLR) in modulating tumorigenesis. In our study, we implicate TLR3 in mediating immune surveillance with increased growth of implanted transgenic adenocarcinoma of the mouse prostate (TRAMP) tumors in TLR3(-/-) compared with TLR3(+/+) mice. Activation of TLR3 by polyinosinic-polycytidylic acid (polyI:C) leads to induction of multiple inflammatory pathways, including NF-kappaB, mitogen-activated protein kinases, and interferon (IFN) regulatory factors. We explored the potential of TLR3 stimulation in prostate cancer immunotherapy and showed that treatment with polyI:C can strongly suppress both s.c. implanted TRAMP tumors in syngenic mice as well as orthotopic prostate cancers in TRAMP C57Bl6 x FvB F1 Tg(+/-) transgenic mice. Treated tumors remained well differentiated to moderately differentiated with increased infiltration of T lymphocytes and natural killer (NK) cells compared with poorly differentiated adenocarcinoma observed in untreated tumors. Like TLR3(-/-) mice, IFN-alpha receptor 1 (IFNAR1)(-/-) mice exhibited reduced tumor surveillance and impaired tumor suppression following polyI:C treatment. We observed that type I IFN-dependent induction of cytokines was responsible for NK activation, with depletion of NK cells leading to increased tumor growth as well as expansion of CD4(+)CD25(+)Foxp3(+) T regulatory lymphocytes. Our study therefore delineates the importance of IFNAR-dependent functions in TLR3-mediated tumor suppression and supports the use of TLR3 agonists for prostate cancer immune-based therapies.

Citing Articles

Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.

Zhang W, Zheng X, Coghi P, Chen J, Dong B, Fan X Front Immunol. 2024; 15:1438030.

PMID: 39206192 PMC: 11349682. DOI: 10.3389/fimmu.2024.1438030.

Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer.

Alaimo A, Genovesi S, Annesi N, De Felice D, Subedi S, Macchia A EMBO J. 2024; 43(5):780-805.

PMID: 38316991 PMC: 10907604. DOI: 10.1038/s44318-024-00040-5.

A Chemically Defined TLR3 Agonist with Anticancer Activity.

Naour J, Thierry S, Scuderi S, Boucard-Jourdin M, Liu P, Bonnin M Oncoimmunology. 2023; 12(1):2227510.

PMID: 37389102 PMC: 10305499. DOI: 10.1080/2162402X.2023.2227510.

The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview.

Veneziani I, Alicata C, Moretta L, Maggi E Biomedicines. 2023; 11(1).

PMID: 36672572 PMC: 9855813. DOI: 10.3390/biomedicines11010064.

Investigation of Toll-like Receptor-2, -3 and -4 Gene Expressions in Larynx Squamous Cell Carcinoma.

Eker C, Inan H, Celebi A, Gozen E, Karaman E Turk Arch Otorhinolaryngol. 2022; 60(3):121-127.

PMID: 36452243 PMC: 9667699. DOI: 10.4274/tao.2022.2022-6-17.

References

Alexopoulou L, Holt A, Medzhitov R, Flavell R . Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001; 413(6857):732-8. DOI: 10.1038/35099560. View

Krieg A . Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008; 27(2):161-7. DOI: 10.1038/sj.onc.1210911. View

Kobayashi K, Hernandez L, Galan J, Janeway Jr C, Medzhitov R, Flavell R . IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002; 110(2):191-202. DOI: 10.1016/s0092-8674(02)00827-9. View

Doyle S, Vaidya S, OConnell R, Dadgostar H, Dempsey P, Wu T . IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 2002; 17(3):251-63. DOI: 10.1016/s1074-7613(02)00390-4. View

Pasare C, Medzhitov R . Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003; 299(5609):1033-6. DOI: 10.1126/science.1078231. View

Kaplan-Lefko P, Chen T, Ittmann M, Barrios R, Ayala G, Huss W . Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003; 55(3):219-37. DOI: 10.1002/pros.10215. View

Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H . Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003; 301(5633):640-3. DOI: 10.1126/science.1087262. View

Kariko K, Ni H, Capodici J, Lamphier M, Weissman D . mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004; 279(13):12542-50. DOI: 10.1074/jbc.M310175200. View

Carson W, Giri J, Lindemann M, Linett M, Ahdieh M, Paxton R . Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994; 180(4):1395-403. PMC: 2191697. DOI: 10.1084/jem.180.4.1395. View

10.

Terme M, Chaput N, Combadiere B, Ma A, Ohteki T, Zitvogel L . Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol. 2008; 180(7):4679-86. DOI: 10.4049/jimmunol.180.7.4679. View

11.

Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S . Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 2008; 58(3):801-12. DOI: 10.1002/art.23268. View

12.

Guerra N, Tan Y, Joncker N, Choy A, Gallardo F, Xiong N . NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008; 28(4):571-80. PMC: 3528789. DOI: 10.1016/j.immuni.2008.02.016. View

13.

Sfanos K, Bruno T, Maris C, Xu L, Thoburn C, DeMarzo A . Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008; 14(11):3254-61. PMC: 3082357. DOI: 10.1158/1078-0432.CCR-07-5164. View

14.

Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A . Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis. 2008; 29(7):1334-42. DOI: 10.1093/carcin/bgn149. View

15.

Cavassani K, Ishii M, Wen H, Schaller M, Lincoln P, Lukacs N . TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med. 2008; 205(11):2609-21. PMC: 2571935. DOI: 10.1084/jem.20081370. View

16.

Rakoff-Nahoum S, Medzhitov R . Toll-like receptors and cancer. Nat Rev Cancer. 2008; 9(1):57-63. DOI: 10.1038/nrc2541. View

17.

Dighe A, Richards E, Old L, Schreiber R . Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994; 1(6):447-56. DOI: 10.1016/1074-7613(94)90087-6. View

18.

Modlin R, Cheng G . From plankton to pathogen recognition. Nat Med. 2004; 10(11):1173-4. DOI: 10.1038/nm1104-1173. View

19.

Kaiser W, Offermann M . Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol. 2005; 174(8):4942-52. DOI: 10.4049/jimmunol.174.8.4942. View

20.

Liew F, Xu D, Brint E, ONeill L . Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005; 5(6):446-58. DOI: 10.1038/nri1630. View